25 related articles for article (PubMed ID: 1506148)
1. MR contrast media in neuroimaging: a critical review of the literature.
Breslau J; Jarvik JG; Haynor DR; Longstreth WT; Kent DL; Maravilla KR
AJNR Am J Neuroradiol; 1999 Apr; 20(4):670-5. PubMed ID: 10319979
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine.
Runge VM; Bronen RA; Davis KR
Invest Radiol; 1992 Aug; 27 Suppl 1():S22-32. PubMed ID: 1506150
[TBL] [Abstract][Full Text] [Related]
4. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of gadoteridol for magnetic resonance imaging of extracranial head and neck pathology.
Zoarski GH; Parker JR; Lufkin RB; Harnsberger HR; Rhoda CH
Invest Radiol; 1992 Aug; 27 Suppl 1():S53-7. PubMed ID: 1506154
[TBL] [Abstract][Full Text] [Related]
6. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
8. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors.
Yuh WT; Fisher DJ; Mayr-Yuh NA; Tali ET; Nguyen HD; Gao F; Ehrhardt JC
Invest Radiol; 1992 Aug; 27 Suppl 1():S39-44. PubMed ID: 1506152
[No Abstract] [Full Text] [Related]
9. The use of MR contrast in nonneoplastic disease of the brain.
Runge VM
Top Magn Reson Imaging; 1995; 7(3):158-67. PubMed ID: 7654394
[TBL] [Abstract][Full Text] [Related]
10. Contrast use at low field: a review.
Desai NK; Runge VM
Top Magn Reson Imaging; 2003 Oct; 14(5):360-4. PubMed ID: 14625464
[TBL] [Abstract][Full Text] [Related]
11. Indication-related dosing for magnetic resonance contrast media.
Yuh WT; Parker JR; Carvlin MJ
Eur Radiol; 1997; 7 Suppl 5():269-75. PubMed ID: 9370558
[TBL] [Abstract][Full Text] [Related]
12. Are Gadolinium-Based Contrast Media Safe Alternatives for Spine Procedures?
Popescu A; Patel J; Smith CC;
Pain Med; 2017 Nov; 18(11):2248-2249. PubMed ID: 29016912
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
